drugset / Trial / NCT01153607

Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers

NCT01153607 ↗

Phase 1 Completed 24 enrolled Lantheus Biosciences Ltd.
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

PET (positron emission tomography) imaging with BAY1006578 for investigation of diagnostic potential in probable Alzheimer Disease patients versus healthy volunteers and radiation dosimetry in healthy volunteers.

Timeline

Start
2010-06
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject BAY1006578 Unknown 190 mbq Intravenous
Subject BAY1006578 Unknown 250 mbq Intravenous

Indications

No indication recorded.